Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy
Open Access
- 30 April 2010
- journal article
- research article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 16 (4), 548-554
- https://doi.org/10.1016/j.bbmt.2009.11.025
Abstract
No abstract availableKeywords
Funding Information
- Masaryk University (LC06027)
- Ministry of Education (MSM0021622415, MSM0021622434, MSM0021620808)
This publication has 34 references indexed in Scilit:
- Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13Blood, 2009
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyélomeBlood, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsLeukemia, 2006
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantationBlood, 2006
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003